METHODS AND COMPOSITIONS FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS
The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells.
1 . A method for inhibiting the growth and/or proliferation of a MYC-driven tumor cell comprising the step of contacting the tumor cell with an inhibitor that inhibits a gene function of at least one of the genes listed in Table 2.
2 . The method of claim 1 , wherein the MYC-driven tumor cell is at least one of the following: a neuroblastoma tumor, a metastatic neuroblastoma tumor, a medulloblastoma, a lymphoma, a rhabdomyosarcoma, a melanoma, a lung cancer, a liver cancer, a breast cancer, a colon cancer, a prostate cancer, an ovarian cancer, or a Burkitt's lymphoma.
3 . The method of claim 1 , wherein the tumor cell is contacted in vitro.
4 . The method of claim 1 , wherein the tumor cell is contacted in vivo in a mammalian subject.
5 . The method of claim 1 , wherein the inhibitor is a small molecule inhibitor that inhibits the function of the gene product.
6 . The method of claim 1 , wherein the inhibitor interferes with the transcription of mRNA from the gene.
7 . The method of claim 1 , wherein the inhibitor interferes with production or expression of the functional gene product of the gene.
8 . The method of claim 1 , wherein the gene is selected from the genes listed in Table 1.
9 . The method of claim 1 , wherein the gene is selected from the group consisting of ALDOA, CECR2, IGF2R, PAK6, PES1, RAD21, REVJL, SUV39H1, TIE1, and CRKRS.
10 . A method of treating a subject suffering from a tumor comprising MYC-driven tumor cells, comprising administering to the subject an amount of a composition comprising an inhibitor that inhibits a gene function of at least one of the genes listed in Table 2 and is effective to inhibit the growth and/or proliferation of the MYC-driven tumor cells.
11 . The method of claim 10 , wherein the MYC-driven tumor cell is at least one of the following: a neuroblastoma tumor, a metastatic neuroblastoma tumor, a medulloblastoma, a lymphoma, a rhabdomyosarcoma, a melanoma, a lung cancer, a liver cancer, a breast cancer, a colon cancer, a prostate cancer, an ovarian cancer, or a Burkitt's lymphoma.
12 . The method of claim 10 , wherein the inhibitor is a small molecule inhibitor that inhibits the function of the gene product.
13 . The method of claim 10 , wherein the inhibitor interferes with the transcription of mRNA from the gene.
14 . The method of claim 10 , wherein the inhibitor interferes with production or expression of the functional gene product of the gene.
15 . The method of claim 10 , wherein the gene is selected from the genes listed in Table 1.
16 . The method of claim 10 , wherein the gene is selected from the group consisting of ALDOA, CECR2, IGF2R, PAK6, PES1, RAD21, REVJL, SUV39H1, TIE1, and CRKRS.